Network based systems

Exagen Inc. Expands Network Access with Evolutions Healthcare Systems

Exagen Inc.

SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that AVISE® testing has entered into a network with Evolutions Healthcare Systems providing access to enhanced care for participating members. The agreement includes Exagen’s AVISE® Lupus and AVISE® CTD tests, making AVISE diagnostic tests available as in-network benefits.

“Exagen continues to expand its presence within the payer community. Partnership with Evolutions Healthcare Systems will allow their participating health plans to offer the AVISE test as an in-network benefit1 to enable rapid and accurate differential diagnosis to improve outcomes for complex autoimmune diseases, including SLE,” said Ron Rocca, President and CEO of Exagen.

About Exagen Inc.

Exagen is dedicated to transforming the continuum of care for patients with debilitating and chronic autoimmune diseases by enabling rapid differential diagnosis and optimizing therapeutic intervention. Exagen has developed and markets a portfolio of innovative test products under its AVISE® brand, many of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable providers to improve patient care through the differential diagnosis, prognosis and monitoring of autoimmune and complex autoimmune diseases, including rheumatoid arthritis and lupus. For more information, please visit www.exagen.com.

About Evolutions Healthcare Systems, Inc.

For 30 years, Evolutions has provided customized provider network solutions to self-insured employers, insurers and third-party administrators through our direct network of hospitals, physicians and specialists. In addition to our network of healthcare professionals, Evolutions offers a comprehensive suite of healthcare management solutions and claims handling services.

Specialties: Development of custom PPO networks for group health, workers’ compensation, automotive, student health plans and international access. IT specialists in network aggregation and claims flow management, repricing and claims review.

For more information, please visit www.ehsppo.com

1Network benefits and coverage are determined by participating health plans.

Forward-looking statements

Exagen cautions you that statements in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen’s current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of positive medical coverage for the AVISE CTD test with Evolutions Healthcare Systems, including the availability and anticipated use of the AVISE CTD test through Evolutions Healthcare Systems. ‘Evolution Healthcare Systems. network, and any potential for increased use of the AVISE CTD laboratory test. The inclusion of forward-looking statements should not be construed as a statement by Exagen that any of its plans will be realized. Actual results may differ from those presented in this press release due to risks and uncertainties inherent in Exagen’s business, including, without limitation: the COVID-19 pandemic may continue to adversely affect our business, our financial condition and results of operations, including as a result of shutdowns of its facilities and operations as well as those of its suppliers and courier services, impeding patient movement and healthcare service disruptions resulting in decreased testing volumes, disruptions to the supply chain of material required for its testing, its sales and marketing activities and its ability to receive samples and perform or deliver its test results, and delays in ongoing and planned clinical trials involving its testing; Exagen’s commercial success is dependent on achieving and maintaining significant market acceptance of its test products and promoted therapeutics among rheumatologists, patients, third-party payers and other community stakeholders. medical; Exagen’s ability to successfully execute its business strategies; third-party payers who fail to provide adequate coverage and reimbursement for Exagen’s test products or promoted therapeutic products; Exagen’s ability to obtain and maintain intellectual property protection for its test products; regulatory changes affecting Exagen’s business; and other risks described in the company’s prior press releases and Exagen’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the company’s annual report on Form 10-K for the fiscal year ended December 31, 2021 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor Relations
Exagen Inc.
Ryan Douglas
[email protected]
760.560.1525

Company
Exagen Inc.
Kamal Adawi, Chief Financial Officer
[email protected]
760.477.5514


Source link